BioAdaptives (BDPT) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 07, 2022
Cover [Abstract]
Entity Registrant Name	BioAdaptives Inc.
Entity Central Index Key	0001575142
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		160,487,511
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-54949
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	46-2592228
Entity Address Address Line 1	2620 Regatta Drive
Entity Address Address Line 2	Suite 102
Entity Address City Or Town	Las Vegas
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89128
City Area Code	702
Local Phone Number	659-8829
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 17,909	$ 82,936
Prepaid expense	0	1,000
Marketable securities	32	190
Inventory	8,000	4,750
Total Current Assets	25,941	88,876
License and patent, net	3,674	59,709
TOTAL ASSETS	29,615	148,585
Current Liabilities:
Accounts payable and accrued liabilities	400,244	247,750
Derivative liabilities	791,095	557,042
Current portion of convertible notes - net of discount of $6,862 and $13,333	423,888	403,117
Note payable - related party	10,246	33,715
Total Current Liabilities	1,625,473	1,241,624
Total Liabilities	1,625,473	1,241,624
Stockholders' Deficit:
Common stock ($.0001 par value, 750,000,000 shares authorized; 132,935,864 and 50,819,780 shares issued and outstanding, and 10,000 issuable, respectively)	13,294	5,082
Additional paid-in capital	5,914,090	5,557,828
Accumulated deficit	(7,523,402)	(6,656,109)
Total Stockholders' Deficit	(1,595,858)	(1,093,039)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	29,615	148,585
Series A Preferred Stock [Member]
Stockholders' Deficit:
Preferred stock value	160	160
Series B Preferred Stock [Member]
Stockholders' Deficit:
Preferred stock value	$ 0	$ 0

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Convertible notes payable current, discount	$ 6,862	$ 13,333
Preferred stock, shares par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	132,935,864	50,819,780
Common stock, shares outstanding	50,819,780	50,819,780
Common stock, shares issuable	10,000	10,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized	4,000,000	4,000,000
Preferred stock, shares issued	1,600,000	1,600,000
Preferred stock, shares outstanding	1,600,000	1,600,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
Revenues	$ 3,337	$ 5,342	$ 13,192	$ 15,925
Cost of revenue	1,337	2,227	7,096	6,962
Gross Profit	2,000	3,115	6,096	8,963
Operating Expenses
General and administrative	43,981	110,456	236,698	152,776
Professional fees	30,588	20,929	102,532	58,551
Stock based compensation	0	0	0	163,900
Amortization of license and patent	4,476	44,583	61,464	92,083
Total Operating Expenses	79,045	175,968	400,694	467,310
Other Income (Expense)
Unrealized gain (loss) on marketable securities	(31)	(423)	(158)	(106)
Interest expense	(94,106)	(64,543)	(199,572)	(141,792)
Change in fair value of derivative liabilities	(105,143)	203,303	(272,965)	(184,420)
Loss on settlement of debt	0	0	0	(51,000)
Total Other Income (Expense)	(199,280)	138,337	(472,695)	(377,318)
Loss before income taxes	(276,325)	(34,516)	(867,293)	(835,665)
Net Loss	$ (276,325)	$ (34,516)	$ (867,293)	$ (835,665)
Net Loss Per Common Share:
Basic and Diluted	$ 0	$ 0	$ (0.01)	$ (0.03)
Weighted Average Number of Common Shares Outstanding:
Basic and Diluted	89,333,996	33,818,539	77,615,330	31,687,123

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)	Total	Preferred Stock Series A	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2020			21,591,942
Balance, amount at Dec. 31, 2020	$ (1,378,785)	$ 0	$ 2,159	$ 4,225,217	$ (5,606,161)
Series A preferred stock issued for settlement of debt - related party, shares		600,000
Series A preferred stock issued for settlement of debt - related party, amount	75,000	$ 60	0	74,940	0
Series A preferred stock issued for license fee, shares		500,000
Series A preferred stock issued for license fee, amount	102,500	$ 50	$ 0	102,450	0
Common stock issued for conversion of debt, shares			10,792,873
Common stock issued for conversion of debt, amount	486,612	0	$ 1,079	485,533	0
Common stock issued for service, shares			1,000,000
Common stock issued for service, amount	163,900	0	$ 100	163,800	0
Cancellation of common stock - officers, shares			(352,390)
Cancellation of common stock - officers, amount	0	0	$ (35)	35	0
Net loss for the period	(491,903)	$ 0	$ 0	0	(491,903)
Balance, shares at Mar. 31, 2021		1,100,000	33,032,425
Balance, amount at Mar. 31, 2021	(1,042,676)	$ 110	$ 3,303	5,051,975	(6,098,064)
Balance, shares at Dec. 31, 2020			21,591,942
Balance, amount at Dec. 31, 2020	(1,378,785)	$ 0	$ 2,159	4,225,217	(5,606,161)
Net loss for the period	(835,665)
Balance, shares at Sep. 30, 2021		1,600,000	35,800,045
Balance, amount at Sep. 30, 2021	(1,212,286)	$ 160	$ 3,580	5,225,800	(6,441,826)
Balance, shares at Mar. 31, 2021		1,100,000	33,032,425
Balance, amount at Mar. 31, 2021	(1,042,676)	$ 110	$ 3,303	5,051,975	(6,098,064)
Net loss for the period	(309,246)	$ 0	$ 0	0	(309,246)
Balance, shares at Jun. 30, 2021		1,100,000	33,032,425
Balance, amount at Jun. 30, 2021	(1,351,922)	$ 110	$ 3,303	5,051,975	(6,407,310)
Series A preferred stock issued for license fee, shares		500,000
Series A preferred stock issued for license fee, amount	91,000	$ 50	$ 0	90,950	0
Common stock issued for conversion of debt, shares			2,767,620
Common stock issued for conversion of debt, amount	83,152	0	$ 277	82,875	0
Net loss for the period	(34,516)	$ 0	$ 0	0	(34,516)
Balance, shares at Sep. 30, 2021		1,600,000	35,800,045
Balance, amount at Sep. 30, 2021	(1,212,286)	$ 160	$ 3,580	5,225,800	(6,441,826)
Balance, shares at Dec. 31, 2021		1,600,000	50,819,780
Balance, amount at Dec. 31, 2021	(1,093,039)	$ 160	$ 5,082	5,557,828	(6,656,109)
Common stock issued for conversion of debt, shares			7,540,799
Common stock issued for conversion of debt, amount	52,017	0	$ 754	51,263	0
Net loss for the period	(367,131)	0	0	0	(367,131)
Debts forgiveness - related party	10,000	$ 0	$ 0	10,000	0
Balance, shares at Mar. 31, 2022		1,600,000	58,360,579
Balance, amount at Mar. 31, 2022	(1,398,153)	$ 160	$ 5,836	5,619,091	(7,023,240)
Balance, shares at Dec. 31, 2021		1,600,000	50,819,780
Balance, amount at Dec. 31, 2021	(1,093,039)	$ 160	$ 5,082	5,557,828	(6,656,109)
Net loss for the period	(867,293)
Balance, shares at Sep. 30, 2022		1,600,000	132,935,864
Balance, amount at Sep. 30, 2022	(1,595,858)	$ 160	$ 13,294	5,914,090	(7,523,402)
Balance, shares at Mar. 31, 2022		1,600,000	58,360,579
Balance, amount at Mar. 31, 2022	(1,398,153)	$ 160	$ 5,836	5,619,091	(7,023,240)
Common stock issued for conversion of debt, shares			19,096,904
Common stock issued for conversion of debt, amount	121,615	0	$ 1,910	119,705	0
Net loss for the period	(223,837)	0	0	0	(223,837)
Warrant issued for Patent's acquisition	5,429	$ 0	$ 0	5,429	0
Balance, shares at Jun. 30, 2022		1,600,000	77,457,483
Balance, amount at Jun. 30, 2022	(1,494,946)	$ 160	$ 7,746	5,744,225	(7,247,077)
Common stock issued for conversion of debt, shares			55,478,381
Common stock issued for conversion of debt, amount	175,413	0	$ 5,548	169,865	0
Net loss for the period	(276,325)	$ 0	$ 0	0	(276,325)
Balance, shares at Sep. 30, 2022		1,600,000	132,935,864
Balance, amount at Sep. 30, 2022	$ (1,595,858)	$ 160	$ 13,294	$ 5,914,090	$ (7,523,402)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (867,293)	$ (835,665)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	0	163,900
Change in fair value of derivative liabilities	272,965	184,420
Amortization of license and patent	61,464	92,083
Amortization of debt discount	161,221	98,481
Loss on settlement of debt	0	51,000
Unrealized loss on investments in marketable securities	158	106
Changes in operating assets and liabilities:
Inventory	(3,250)	4,214
Prepaid expense and other current assets	1,000	(1,000)
Accounts payable and accrued liabilities	172,177	119,213
Due to related party	1,803	0
Net Cash Used in Operating Activities	(199,755)	(123,248)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceed from related party	1,623	1,623
Repayment to related party	(1,623)	(1,623)
Repayment of notes payable - related party	(25,272)	(20,000)
Proceeds from convertible notes	160,000	205,000
Net Cash Provided by Financing Activities	134,728	185,000
Net change in cash	(65,027)	61,752
Cash at beginning of period	82,936	4,587
Cash at end of period	17,909	66,339
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	0	0
Cash paid for interest	4,728	16,424
NON-CASH INVESTING AND FINANCING ACTIVITIES
Derivative liability recognized as debt discount	142,000	120,000
Issuance of common stock for conversion of debt	349,045	569,764
Issuance Series A preferred stock for license fee	0	193,500
Issuance Series A preferred stock for settlement of debt - related party	0	60
Debts forgiveness - related party	10,000	0
Warrant issued for Patent's acquisition	5,429	0
Cancellation of common stock	$ 0	$ 35

DESCRIPTION OF BUSINESS AND HIS

DESCRIPTION OF BUSINESS AND HISTORY	9 Months Ended
	Sep. 30, 2022
DESCRIPTION OF BUSINESS AND HISTORY
1. DESCRIPTION OF BUSINESS AND HISTORY	1. DESCRIPTION OF BUSINESS AND HISTORY Description of business BioAdaptives, Inc. (“BioAdaptives” or the “Company”) was incorporated in Delaware on April 19, 2013, under the name Apex 8, Inc. Shortly afterwards, the Company’s control person sold his interest; new owners appointed management and changed its name to BioAdaptives, Inc. The Company acquired assets relating to the investigation, development and marketing of nutraceutical products; equipment designed to improve the bioavailability of nutrients in humans and animals; and licenses for specific products. We commenced investigation of the role of various botanicals in primitive cell development and proliferation, including certain algae along with herbs used in Traditional Chinese Medicine and Ayurvedic Practice. In the course of this investigation, BioAdaptives identified several potential human and animal products. The Company terminated further work on the equipment and products licensed in its early stages to concentrate on these products, for both human and animals. The Company’s current nutraceutical products are natural plant- and algal-based dietary supplements for humans and animals developed with our knowledge of natural foods. Our product lines include PluriCell®, PluriPain®, and PrimiLung™ for humans along with Equine All-in-One™ and a related Booster for horses. Our human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. The science behind our products has proven to be effective for performance enhancement and pain relief for horses and dogs as well as providing improvements in appearance and we have developed products to utilize these advances. The Company also markets the Lung Cleanser™ medical device, which is sold with our PrimiLung® product as part of a Lung Armor™ package. Additionally, during this reporting period, the Company acquired patent rights to a method to embed oxygen in water and is developing commercial products based on this technology that will augment and complement our current product lines. All of these products are sold under licensing and manufacturing agreements with third-parties and our current activities are reliant on marketing and distributing products developed and owned by others. In February 2022, the Company acquired US Patent rights to a process that increases dissolved oxygen in water. The process produces MorO2, ingestion of which is believed to increase diffusion of oxygen into muscle tissues. The Company is developing a business plan to manufacture and market products based on the MorO2 technology. The Company’s corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128, and it maintains fulfillment facilities at 4385 Cameron Street, Suite B, Las Vegas, NV 89103. COVID-19 A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. Additional strains of COVID-19 are currently in circulation, and the CDC has stated that the virus will continue to impact the US population. As a result of the outbreak, many companies have experienced disruptions in their operations and in markets served. The Company has instituted some and may take additional temporary precautionary measures intended to help ensure the well-being of its employees and minimize business disruption. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company’s results of operations and financial position on September 30, 2022. The full extent of the future impacts of COVID-19 on the Company’s operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to collect accounts receivable and the ability of the Company to continue to provide high quality services to its clients. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur, and additional information is obtained.

SUMMARY OF SIGNIFICANT POLICIES

SUMMARY OF SIGNIFICANT POLICIES	9 Months Ended
	Sep. 30, 2022
SUMMARY OF SIGNIFICANT POLICIES
2. SUMMARY OF SIGNIFICANT POLICIES	2. SUMMARY OF SIGNIFICANT POLICIES Basis of presentation The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10K filed with SEC on March 31, 2022, have been omitted. Consolidation The accompanying consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries, Blenders Choice Inc and MORO2, Inc. All inter-company balances and transactions have been eliminated. The Company and its subsidiary will be collectively referred to herein as the “Company.” Use of estimates The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates. Earnings (loss) per share Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive. Financial Instruments and Fair Value Measurements As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The following table summarizes fair value measurements by level on September 30, 2022, and December 31, 2021, measured at fair value on a recurring basis: Fair Value Measurements as of September 30, 2022, Using: Total Carrying Value Quoted Market Prices in Active Significant Other Observable Significant Unobservable as of September 30, Markets Inputs Inputs 2022 (Level 1) (Level 2) (Level 3) Assets: Equity Securities $ 32 $ 32 $ - $ - Liabilities Derivative liabilities $ 791,095 $ - $ - $ 791,095 Fair Value Measurements as of December 31, 2021, Using: Total Carrying Value as of December 31, Quoted Market Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs 2021 (Level 1) (Level 2) (Level 3) Assets: Equity Securities $ 190 $ 190 $ - $ - Liabilities Derivative liabilities $ 557,042 - - 557,042 Intangible Assets The Company capitalizes certain costs to acquire intangible assets; if such assets are determined to have a finite useful life they are amortized on a straight-line basis over the estimated useful life. The Company tests its intangible assets for impairment at least annually and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company’s expected future cash flows; a sustained, significant decline in the Company’s stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the Company’s segments; unanticipated competition; and slower growth rates. Recent Accounting Pronouncements The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial statements.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2022
GOING CONCERN
3. GOING CONCERN	3. GOING CONCERN The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $7,523,402 as of September 30, 2022. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties. In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

MARKETABLE SECURITIES

MARKETABLE SECURITIES	9 Months Ended
	Sep. 30, 2022
MARKETABLE SECURITIES
4. MARKETABLE SECURITIES	4. MARKETABLE SECURITIES Equity securities on September 30, 2022, and December 31, 2021, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of $32 and $190, respectively.

LICENSE AND PATENT

LICENSE AND PATENT	9 Months Ended
	Sep. 30, 2022
LICENSE AND PATENT
5. LICENSE AND PATENT	5. LICENSE AND PATENT During the year ended December 31, 2021, the Company entered into three license and royalty agreements for human and animal nutraceutical products, which it currently markets. These agreements are for a period of one year and the Company issued 1,000,000 shares of Series A preferred stock valued at $193,500 in consideration of these licenses. The Company has capitalized the costs associated with licenses. During the nine months ended September 30, 2022, and 2021, the Company recognized $59,709 and $47,500 in amortization expenses of license fees, respectively. As of September 30, 2022, and December 31, 2021, the asset value of the licenses was $0 and $59,709, respectively. On February 2, 2022, the Company entered in a Patent Purchase and Consulting Agreement (“Agreement”) with an individual as inventor of the technology identified in and owns US Patent No. U.S. Patent 9,783,432B (the “Patent”), which covers technology used in enhancing the capability of water to hold significantly larger amounts of oxygen. The Company granted 1,000,000 shares warrant and has capitalized the cost of $5,429 as patent During the nine months ended September 30, 2022, the Company recognized $1,755 in amortization expenses of patent cost. As of September 30, 2022, the asset value of the patent was $3,674.

ACCOUNTS PAYABLE AND ACCRUED LI

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	9 Months Ended
	Sep. 30, 2022
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities on September 30, 2022, and December 31, 2021, consist of the following. September 30, December 31, 2022 2021 Accounts payable $ 5,340 $ 1,750 Accrued salary 300,000 166,666 Accrued interest 92,282 68,341 Accrued liabilities 2,622 10,993 $ 400,244 $ 247,750

CONVERTIBLE NOTES

CONVERTIBLE NOTES	9 Months Ended
	Sep. 30, 2022
CONVERTIBLE NOTES
7. CONVERTIBLE NOTES	7. CONVERTIBLE NOTES Convertible notes on September 30, 2022, and December 31, 2021, consists of the following: September 30, December 31, 2022 2021 Convertible Notes - originated in April 2018 $ 95,000 $ 95,000 Convertible Notes - originated in June 2018 166,000 166,000 Convertible Notes - originated in October 2018 50,000 50,000 Convertible Notes - issued fiscal year 2021 - 105,450 Convertible Notes - issued fiscal year 2022 119,750 - Total convertible notes payable 430,750 416,450 Less: Unamortized debt discount (6,862 ) (13,333 ) Total convertible notes 423,888 403,117 Less: current portion of convertible notes 423,888 403,117 Long-term convertible notes $ - $ - For the nine months ended September 30, 2022, and 2021, the interest expense on convertible notes was $37,903 and $41,847, respectively. As of September 30, 2022, and December 31, 2021, the accrued interest was $91,320 and $63,100, respectively. The Company recognized amortization expense related to the debt discount of $161,221 and $98,481 for the nine months ended September 30, 2022, and 2021, respectively, which is included in interest expense in the statements of operation. Conversion During the nine months ended September 30, 2022, the Company converted notes with principal amounts of $158,450 and accrued interest of $9,683 into 82,116,084 shares of common stock. The corresponding derivative liability at the date of conversion of $180,912 was credited to additional paid in capital. Convertible Notes - Issued during the year ended December 31, 2018 During the year ended December 31, 2018, the Company issued a total principal amount of $426,000 convertible notes for cash proceeds of $426,000. The convertible notes were also provided with a total of 107,000 common shares valued at $22,210. The terms of convertible notes are summarized as follows: · Term two years; · Annual interest rates 12%; · Convertible at the option of the holders at any time · Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price. Convertible Notes - Issued during the year ended December 31, 2021 During the year ended December 31, 2021, the Company issued a total principal amount of $277,500 in convertible note for cash proceeds of $257,000. The terms of convertible note are summarized as follows: · Term one year; · Annual interest rates 10%; · Convertible at 180 days from issuance · Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date. Convertible Notes - Issued during the year ended December 31, 2022 During the nine months ended September 30, 2022, the Company issued a total principal amount of $172,750 in convertible notes for cash proceeds of $160,000. The terms of convertible notes are summarized as follows: · Term one year; · Annual interest rates 10%; · Convertible at 180 days from issuance · Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date. The Company valued the conversion feature using the Black-Scholes pricing model. The fair value of the derivative liability for all the notes that became convertible, including the notes issued in prior years, during the nine months ended September 30, 2022, amounted to $186,933, and $142,000 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $44,933 was recognized as a “day 1” derivative loss.

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES	9 Months Ended
	Sep. 30, 2022
DERIVATIVE LIABILITIES
8. DERIVATIVE LIABILITIES	8. DERIVATIVE LIABILITIES The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options. Fair Value Assumptions Used in Accounting for Derivative Liabilities. ASC 815 requires we assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item. The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of September 30, 2022. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model. For the nine months ended September 30, 2022, and year ended December 31, 2021, the estimated fair values of the liabilities measured on a recurring basis are as follows: Nine Months Ended Year ended September 30, December 31, 2022 2021 Expected term 0.06 - 0.51 years 0.02- 0.51 years Expected average volatility 72% - 164% 128% - 315% Expected dividend yield - - Risk-free interest rate 0.17% - 3.28% 0.03% - 0.07% The following table summarizes the changes in the derivative liabilities during the nine months ended September 30, 2022. Fair Value Measurements Using Significant Observable Inputs (Level 3) Balance - December 31, 2021 $ 557,042 Addition of new derivatives recognized as debt discounts 142,000 Addition of new derivatives recognized as loss on derivatives 44,933 Settled on issuance of common stock (180,912 ) (Gain) loss on change in fair value of the derivative 228,032 Balance - September 30, 2022 $ 791,095 The aggregate loss on derivatives during the nine months ended September 30, 2022, and 2021 was as follows: Nine Months Ended September 30, 2022 2021 Day one loss due to derivative liabilities on convertible notes $ 44,933 $ 143,392 Loss on change in fair value of the derivative liabilities 228,032 41,028 $ 272,965 $ 184,420

STOCKHOLDERS EQUITY

STOCKHOLDERS EQUITY	9 Months Ended
	Sep. 30, 2022
STOCKHOLDERS EQUITY
9. STOCKHOLDERS' EQUITY	9. STOCKHOLDERS’ EQUITY Preferred Stock On January 24, 2022, the Board of Directors of the Company’s, approved for an increase in the number of authorized shares of the Company’s preferred stock from 5,000,000 shares to 10,000,000 shares. The Company is authorized to issue 10,000,000 shares of $0.001 par value preferred stock, of which 4,000,000 have been designated as Series A Preferred Stock and 6,000,000 have been designated as Series B Preferred Stock. Series A Preferred Stock On February 6, 2020, the Company established its Series A Preferred Stock, par value 0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series A Preferred Stock. The Company may use the Series A Preferred Stock for the purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series A Preferred Stock have enhanced voting privileges under certain circumstances; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 5:1 ratio. There are 1,600,000 shares of Series A shares issued as of the date of this filing. Series B Preferred Stock Effective January 26, 2022, the Company established its Series B Preferred Stock, par value 0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 6,000,000 shares of Series B Preferred Stock. The Company may use the Series B Preferred Stock for purpose of asset acquisition or other financing purposes. The Series B Preferred Stock have enhanced (100:1) voting privileges; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 10:1 ratio. There are no Series B shares issued as of the date of this filing. Common Stock On January 24, 2022, the holders of a majority of the Company’s outstanding voting stock, approved for an increase in the number of authorized shares of the Company’s common stock from 200,000,000 shares to 750,000,000 shares. During the nine months ended September 30, 2022, the Company issued 82,116,084 shares of common stock valued at $349,045 for conversion of debt. As of September 30, 2022, and December 31, 2021, there were 132,925,864 and 50,809,780 shares of the Company’s common stock issued and outstanding, respectively. In addition, as of September 30, 2022, and December 31, 2021, there were 10,000 shares of the Company’s common stock issuable. Warrant On February 6, 2022, in conjunction with purchase of patent, the Company granted 1,000,000 shares for period of two years with exercise price of $0.006 per share. The fair value of granted shares at the issuance date was $5,429. The Company recorded warrant as additional paid-in-capital. For the nine months ended September 30, 2022, the estimated fair values of the warrant measured on a recurring basis are as follows: Nine months Ended September 30, 2022 Expected term 2.00 years Expected average volatility 235 % Expected dividend yield - Risk-free interest rate 1.31 %

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2022
RELATED PARTY TRANSACTIONS
10. RELATED PARTY TRANSACTIONS	10. RELATED PARTY TRANSACTIONS Notes payable - related party During the nine months ended September 30, 2022, and 2021, the Company repaid notes payable of $25,272 and $20,000 and accrued interest of $4,728 and $0 to a related party, respectively. During the nine months ended September 30, 2022, and 2021, the Company recognized interest of $448 and $1,464, respectively. As of September 30, 2022, and December 31, 2021, the Company recorded notes payable - related party of $8,443 and $33,715 and accrued interest of $961 and $5,241, respectively. The note is a 4% interest bearing promissory note that the term is 1 year. Due to related party During the nine months ended September 30, 2022, Dr. Edward E. Jacobs, M.D., our CEO, advanced $2,346 for operating expenses and $543 was reimbursed. As of September 30, 2022, due to related party of $1,803. Employee agreements On January 1, 2022, the Company entered into a Restricted Stock Unit Termination Agreement for modification of employment agreements signed during 2021 with Dr. Edward E. Jacobs, M.D, Charles Townsend and Robert Ellis. The employees agreed to waive all rights under previously issued RSUs as of January 1, 2022, in exchange for one -time issuance 100,000 shares of restricted common stock. In addition, the Employment Agreement was modified to provide for compensation in the form of a number of Warrants, equivalent to twice (2X) the number of shares previously payable in RSUs and the exercise price of the Warrant shall be the OTC Market price of the Company’s common shares. During the nine months ended September 30, 2022, the Company accrued salary of $133,334. Debt forgiveness During the nine months ended September 30, 2022, the Company recognized $10,000 accrued salary payable to Robert Ellis related to year 2020 as additional paid-in -capital, based on released agreement in year 2020 due to COVID-19-based financial and other considerations.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
SUBSEQUENT EVENTS
12. SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure.

SUMMARY OF SIGNIFICANT POLICI_2

SUMMARY OF SIGNIFICANT POLICIES (Policies)	9 Months Ended
	Sep. 30, 2022
SUMMARY OF SIGNIFICANT POLICIES
Basis of presentation	The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10K filed with SEC on March 31, 2022, have been omitted.
Consolidation	The accompanying consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries, Blenders Choice Inc and MORO2, Inc. All inter-company balances and transactions have been eliminated. The Company and its subsidiary will be collectively referred to herein as the “Company.”
Use of estimates	The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Earnings (loss) per share	Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.
Financial Instruments and Fair Value Measurements	As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The following table summarizes fair value measurements by level on September 30, 2022, and December 31, 2021, measured at fair value on a recurring basis: Fair Value Measurements as of September 30, 2022, Using: Total Carrying Value Quoted Market Prices in Active Significant Other Observable Significant Unobservable as of September 30, Markets Inputs Inputs 2022 (Level 1) (Level 2) (Level 3) Assets: Equity Securities $ 32 $ 32 $ - $ - Liabilities Derivative liabilities $ 791,095 $ - $ - $ 791,095 Fair Value Measurements as of December 31, 2021, Using: Total Carrying Value as of December 31, Quoted Market Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs 2021 (Level 1) (Level 2) (Level 3) Assets: Equity Securities $ 190 $ 190 $ - $ - Liabilities Derivative liabilities $ 557,042 - - 557,042
Intangible Assets	The Company capitalizes certain costs to acquire intangible assets; if such assets are determined to have a finite useful life they are amortized on a straight-line basis over the estimated useful life. The Company tests its intangible assets for impairment at least annually and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company’s expected future cash flows; a sustained, significant decline in the Company’s stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the Company’s segments; unanticipated competition; and slower growth rates.
Recent Accounting Pronouncements	The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial statements.

SUMMARY OF SIGNIFICANT POLICI_3

SUMMARY OF SIGNIFICANT POLICIES (Tables)	9 Months Ended
	Sep. 30, 2022
SUMMARY OF SIGNIFICANT POLICIES
Schedule of Fair Value of Measurements of Assets on Recurring Basis	Total Carrying Value Quoted Market Prices in Active Significant Other Observable Significant Unobservable as of September 30, Markets Inputs Inputs 2022 (Level 1) (Level 2) (Level 3) Assets: Equity Securities $ 32 $ 32 $ - $ - Liabilities Derivative liabilities $ 791,095 $ - $ - $ 791,095 Total Carrying Value as of December 31, Quoted Market Prices in Active Markets Significant Other Observable Inputs Significant Unobservable Inputs 2021 (Level 1) (Level 2) (Level 3) Assets: Equity Securities $ 190 $ 190 $ - $ - Liabilities Derivative liabilities $ 557,042 - - 557,042

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2022
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Schedule of Accounts Payable and Accrued Liabilities	September 30, December 31, 2022 2021 Accounts payable $ 5,340 $ 1,750 Accrued salary 300,000 166,666 Accrued interest 92,282 68,341 Accrued liabilities 2,622 10,993 $ 400,244 $ 247,750

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	9 Months Ended
	Sep. 30, 2022
CONVERTIBLE NOTES (Tables)
Schedule of Convertible Notes	September 30, December 31, 2022 2021 Convertible Notes - originated in April 2018 $ 95,000 $ 95,000 Convertible Notes - originated in June 2018 166,000 166,000 Convertible Notes - originated in October 2018 50,000 50,000 Convertible Notes - issued fiscal year 2021 - 105,450 Convertible Notes - issued fiscal year 2022 119,750 - Total convertible notes payable 430,750 416,450 Less: Unamortized debt discount (6,862 ) (13,333 ) Total convertible notes 423,888 403,117 Less: current portion of convertible notes 423,888 403,117 Long-term convertible notes $ - $ -

DERIVATIVE LIABILITIES (Tables)

DERIVATIVE LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2022
DERIVATIVE LIABILITIES
Schedule of Estimated Fair Values of Liabilities Measured on Recurring Basis	Nine Months Ended Year ended September 30, December 31, 2022 2021 Expected term 0.06 - 0.51 years 0.02- 0.51 years Expected average volatility 72% - 164% 128% - 315% Expected dividend yield - - Risk-free interest rate 0.17% - 3.28% 0.03% - 0.07%
Summary of Changes in Derivative Liabilities	Fair Value Measurements Using Significant Observable Inputs (Level 3) Balance - December 31, 2021 $ 557,042 Addition of new derivatives recognized as debt discounts 142,000 Addition of new derivatives recognized as loss on derivatives 44,933 Settled on issuance of common stock (180,912 ) (Gain) loss on change in fair value of the derivative 228,032 Balance - September 30, 2022 $ 791,095
Schedule of Loss on Derivatives	Nine Months Ended September 30, 2022 2021 Day one loss due to derivative liabilities on convertible notes $ 44,933 $ 143,392 Loss on change in fair value of the derivative liabilities 228,032 41,028 $ 272,965 $ 184,420

STOCKHOLDERS EQUITY (Tables)

STOCKHOLDERS EQUITY (Tables)	9 Months Ended
	Sep. 30, 2022
STOCKHOLDERS EQUITY
Schedule of Estimated Fair Values of Warrant Measured on Recurring Basis	Nine months Ended September 30, 2022 Expected term 2.00 years Expected average volatility 235 % Expected dividend yield - Risk-free interest rate 1.31 %

SUMMARY OF SIGNIFICANT POLICI_4

SUMMARY OF SIGNIFICANT POLICIES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Marketable securities	$ 32	$ 190
Derivative liabilities	791,095	557,042
Fair Value, Inputs, Level 2 [Member]
Marketable securities	0	0
Derivative liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Marketable securities	0	0
Derivative liabilities	791,095	557,042
Fair Value, Inputs, Level 1 [Member]
Marketable securities	32	190
Derivative liabilities	$ 0	$ 0

SUMMARY OF SIGNIFICANT POLICI_5

SUMMARY OF SIGNIFICANT POLICIES (Details Narrative)	9 Months Ended
	Sep. 30, 2022
SUMMARY OF SIGNIFICANT POLICIES
Owned subsidiaries, Percentage	100%

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
GOING CONCERN
Accumulated deficit	$ (7,523,402)	$ (6,656,109)

MARKETABLE SECURITIES (Details

MARKETABLE SECURITIES (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Marketable securities	$ 32	$ 190
Hemp Inc [Member]
Equity securities held	105,736	105,736

LICENSE AND PATENT (Details Nar

LICENSE AND PATENT (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Feb. 28, 2022	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Dec. 31, 2021
Amortization of license fee		$ 59,709	$ 47,500
Asset value of license cost				$ 0	$ 59,709
Amortization of patent cost		$ 1,755
Asset value of the patent				$ 3,674
Shares issued upon consideration transferred		82,116,084
Agreement [Member]
Number of warrent granted shares	1,000,000
Cost incurred for warrant granted as patent	$ 5,429
Series A Preferred Stock [Member]
Shares issued upon consideration transferred		1,000,000
Shares issued upon consideration transferred, value		$ 193,500

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable	$ 5,340	$ 1,750
Accrued salary	300,000	166,666
Accrued interest	92,282	68,341
Accrued liabilities	2,622	10,993
Accounts Payable And Accrued Liabilities	$ 400,244	$ 247,750

CONVERTIBLE NOTES (Details)

CONVERTIBLE NOTES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Total convertible notes payable	$ 430,750	$ 416,450
Less: Unamortized debt discount	(6,862)	(13,333)
Total convertible notes	423,888	403,117
Less: current portion of convertible notes	423,888	403,117
Long-term convertible notes	0	0
Issued fiscal year 2022 [Member] | Convertible Notes Payable [Member]
Total convertible notes payable	119,750	0
originated in April 2018 [Member] | Convertible Notes Payable [Member]
Total convertible notes payable	95,000	95,000
Originated in June 2018 [Member] | Convertible Notes Payable [Member]
Total convertible notes payable	166,000	166,000
Originated in October 2018 [Member] | Convertible Notes Payable [Member]
Total convertible notes payable	50,000	50,000
Issued fiscal year 2021 [Member] | Convertible Notes Payable [Member]
Total convertible notes payable	$ 0	$ 105,450

CONVERTIBLE NOTES (Details Narr

CONVERTIBLE NOTES (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2018
Debt discount	$ 186,933	$ 142,000
Derivative loss	44,933
Amortization of debt discount	161,221	98,481
Interest expenses	37,903	$ 41,847
Fiar value of derivatives liabilities	180,912
Accrued interest	91,320		$ 63,100
Accrued interest of convertible notes	9,683
Principal amount of convertible notes	$ 158,450
Convertible shares of common stock	82,116,084
Debt instrument converted amount shares issued	82,116,084
Convertible Notes Payable [Member]
Principal amount of convertible notes	$ 172,750		$ 277,500	$ 426,000
Description of conversion price	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date		Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date	Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price
Proceeds from Convertible notes	$ 160,000		$ 257,000	$ 426,000
Debt instrument converted amount				$ 22,210
Debt instrument converted amount shares issued				107,000
Convertible debt term	1 year		1 year	2 years
Annual interest rates	10%		10%	12%
Debt Instrument, Convertible, Terms of Conversion Feature	Convertible at 180 days from issuance		Convertible at 180 days from issuance	Convertible at the option of the holders at any time

DERIVATIVE LIABILITIES (Details

DERIVATIVE LIABILITIES (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Expected dividend yield	0%	0%
Expected term	2 years
Expected average volatility	235%
Risk-free interest rate	1.31%
Minimum [Member]
Expected term	21 days	7 days
Expected average volatility	72%	128%
Risk-free interest rate	0.17%	0.03%
Maximum [Member]
Expected term	6 months 3 days	6 months 3 days
Expected average volatility	164%	315%
Risk-free interest rate	3.28%	0.07%

DERIVATIVE LIABILITIES (Detai_2

DERIVATIVE LIABILITIES (Details 1) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
DERIVATIVE LIABILITIES
Beginnig Balance	$ 557,042
Addition of new derivatives recognized as debt discounts	142,000
Addition of new derivatives recognized as loss on derivatives	44,933
Settled on issuance of common stock	(180,912)
Loss on change in fair value of the derivative	228,032	$ 41,028
Ending Balance	$ 791,095

DERIVATIVE LIABILITIES (Detai_3

DERIVATIVE LIABILITIES (Details 2) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
DERIVATIVE LIABILITIES (Details)
Day one loss due to derivative liabilities on convertible notes	$ 44,933	$ 143,392
Loss on change in fair value of the derivative liabilities	228,032	41,028
Aggregate (gain) loss on derivatives	$ 272,965	$ 184,420

STOCKHOLDERS EQUITY (Details)

STOCKHOLDERS EQUITY (Details)	9 Months Ended
	Sep. 30, 2022
STOCKHOLDERS EQUITY
Expected term	2 years
Expected average volatility	235%
Expected dividend yield	0%
Risk-free interest rate	1.31%

STOCKHOLDERS EQUITY (Details Na

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)			1 Months Ended	9 Months Ended
	Feb. 06, 2022	Feb. 06, 2020	Jan. 26, 2022	Sep. 30, 2022	Sep. 30, 2021	Jan. 24, 2022	Dec. 31, 2021
Preferred stock, shares authorized				10,000,000		10,000,000	10,000,000
Preferred stock, shares par value				$ 0.001
Debt instrument converted amount				$ 349,045
Common stock shares issused upon conversion of debt				82,116,084
Common stock, shares outstanding				50,809,780			50,809,780
Common stock, shares issued				132,925,864			132,925,864
Common stock, shares authorized				750,000,000		750,000,000	750,000,000
Common stock, shares granted	1,000,000
Exercise price	$ 0.006
Common stock, shares issuable				10,000			10,000
Fair value of shares granted	$ 5,429			$ 272,965	$ 184,420
Preferred stock, shares par value				$ 0.0001			$ 0.0001
Series A Preferred Stock [Member]
Preferred stock, shares authorized		4,000,000		4,000,000			4,000,000
Common stock shares issused upon conversion of debt				1,000,000
Preferred stock, shares par value		$ 0.0001
Conversion common rights		at a 5:1 ratio
Preferred stock, shares issued				1,600,000			1,600,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized			6,000,000	6,000,000			6,000,000
Preferred stock, shares par value			$ 0.0001
Conversion common rights			at a 10:1 ratio
Preferred stock, shares issued				0			0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Accrued interest			$ 4,728	$ 0
Rate of interest			4%
Repayment of notes payable - related party			$ 25,272	20,000
Notes payable- related party noncurrent	$ 8,443		8,443		$ 33,715
Interest amount			448	1,464
Notes payable - accrued interest	961		961		$ 5,241
Accrued salary payable			10,000
Accrued salary			133,334
Operating expenses	79,045	$ 175,968	400,694	$ 467,310
CEO [Member]
Operating expenses			2,346
Rimburshment amount			543
Due to related party	$ 1,803		$ 1,803
President [Member] | January 1, 2021 [Member] | Restricted Stock Units (RSUs) [Member] | Employment Agreement [Member]
Issuance of share			100,000